GLYC - GlycoMimetics, Inc.
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.8000 |
| Open | 1.8300 |
| Bid | 1.8100 x 4000 |
| Ask | 1.8800 x 1000 |
| Day's Range | 1.7800 - 1.8300 |
| 52 Week Range | 0.5100 - 4.1600 |
| Volume | |
| Avg. Volume | 300,123 |
| Market Cap | 131.704M |
| Beta (5Y Monthly) | 2.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6900 |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
Fair Value
Related Research
Business WireGlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
ROCKVILLE, Md., May 31, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023 at 4:00 p.m. ET.
Simply Wall St.retail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last week
Key Insights The considerable ownership by retail investors in GlycoMimetics indicates that they collectively have a...
- Thomson Reuters StreetEvents
Q1 2023 GlycoMimetics Inc Earnings Call
Q1 2023 GlycoMimetics Inc Earnings Call
Business WireGlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
ROCKVILLE, Md., May 03, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the first quarter ended March 31, 2023. Cash and cash equivalents as of March 31, 2023 were $65.0 million.
Business WireGlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
ROCKVILLE, Md., April 26, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET.
- Simply Wall St.
Possible turnaround for GlycoMimetics, Inc. (NASDAQ:GLYC) insiders, still down US$63k after a US$732k shopping spree
Insiders who purchased US$732k worth of GlycoMimetics, Inc. ( NASDAQ:GLYC ) shares over the past year recouped some of...
InvestorPlaceThe Quant Trading System Picking Stocks That Soar 300%
Editor’s note: “The Quant Trading System Picking Stocks That Soar 300%” was previously published in January 2023. It has since been updated to include the most relevant information available. The stock market got crushed in 2022. It was a nasty year for most investors. But what if I told you that amid 2022’s financial market turmoil, there was a quantitative trading system that was regularly picking stocks that were soaring 100%, 200%, and even 300%-plus in a matter of months? InvestorPlace - St
Insider MonkeyGlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2022 Earnings Call Transcript
GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2022 Earnings Call Transcript March 29, 2023 Operator: Good morning. And thank you for joining the GlycoMimetics Fourth Quarter and Full Year 2022 Earnings Call. At this time, all participants are in a listen only mode. Following the management’s remarks, we will hold a question-and-answer session at that time, lines will […]
Business WireGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
ROCKVILLE, Md., March 29, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2022. Cash and cash equivalents as of December 31, 2022 were $47.9 million. After year-end, the company raised an additional $28.7 million in net proceeds from its "at-the-market" (ATM) sales facili
Business WireGlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
ROCKVILLE, Md., March 16, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m. ET.
Business WireGlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference
ROCKVILLE, Md., March 01, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 43rd Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2023 at 12:50 p.m. ET.
Business WireGlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md., February 16, 2023--GlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on February 10, 2023 of a non-qualified stock option award to purchase an aggregate of 150,000 shares to Chinmaya Rath, the Company’s new Senior Vice President and Chief Business Officer. The award was granted as an inducement equity award outside of the Company’s Amended and Restated 2013 Equity Incentive Plan
Business WireGlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee
ROCKVILLE, Md., February 15, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the independent Data Monitoring Committee (DMC) reviewed the interim utility analysis of its Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML) and recommended the study should continue to the originally planned final overall survival event trigger.
TheStreet.comThis Small Pharma Company Could Develop Into a Nice Trade
Let's see how to trade GlycoMimetics, a clinical-stage drug developer focused on a type of cancer treatment.
- Simply Wall St.
GlycoMimetics, Inc.'s (NASDAQ:GLYC) Shift From Loss To Profit
With the business potentially at an important milestone, we thought we'd take a closer look at GlycoMimetics, Inc.'s...
- Simply Wall St.
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
ZacksIs Axonics (AXNX) Outperforming Other Medical Stocks This Year?
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
Business WireGlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting
ROCKVILLE, Md., December 12, 2022--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced results from two investigator-sponsored trials studying uproleselan in patients with acute myeloid leukemia (AML). These results were presented at the 64th American Society of Hematology (ASH) Annual Meeting.
- Simply Wall St.
Individual investors account for 44% of GlycoMimetics, Inc.'s (NASDAQ:GLYC) ownership, while hedge funds account for 18%
If you want to know who really controls GlycoMimetics, Inc. ( NASDAQ:GLYC ), then you'll have to look at the makeup of...
ZacksIs GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?
Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
ZacksAfter Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
- Zacks
Are Medical Stocks Lagging Axonics (AXNX) This Year?
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
- Simply Wall St.
GlycoMimetics Third Quarter 2022 Earnings: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021)
GlycoMimetics ( NASDAQ:GLYC ) Third Quarter 2022 Results Key Financial Results Net loss: US$8.52m (loss narrowed by 51...
- Simply Wall St.
Insiders at GlycoMimetics, Inc. (NASDAQ:GLYC) recouped some losses this week after buying this year, still down US$49k
Some of the losses seen by insiders who purchased US$82k worth of GlycoMimetics, Inc. ( NASDAQ:GLYC ) shares over the...
Business WireGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
ROCKVILLE, Md., November 09, 2022--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2022. Cash and cash equivalents as of September 30, 2022, were $51.6 million.